Sutro Biopharma Cash Flow Reinvestment Rate
Sutro Biopharma cash flow reinvestment rate. Sutro Biopharma (STRO) has a Cash Flow Reinvestment Rate of 8.58x as of June 2024, reinvesting $81.13 Million (capex $756.00K plus investments $-80.38 Million) from operating cash flow of $9.46 Million. Explore cash flow to debt ratio of Sutro Biopharma to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Sutro Biopharma (2018–2022)
Cash flow reinvestment rate of Sutro Biopharma from 2018 to 2022. Historical reinvestment intensity for Sutro Biopharma across 2 annual periods. Explore STRO capital expenditure intensity to see what proportion of operating cash flow is directed to capital expenditures.
Sutro Biopharma Cash Flow Reinvestment Rate by Year (2018–2022)
Sutro Biopharma cash flow reinvestment rate by year from 2018 to 2022. Year-by-year capital reinvestment analysis for Sutro Biopharma. For the full cash flow conversion analysis, see STRO cash generation efficiency.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2022 | 12.08x | $42.88 Million | $3.55 Million | $7.86 Million | ▲ +90.9% |
| 2018 | 6.33x | $80.27 Million | $12.68 Million | $1.56 Million | — |